<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3389/fmed.2020.00226</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reiter</surname><given-names>Russel J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/11459/overview"/></contrib><contrib contrib-type="author"><name><surname>Abreu-Gonzalez</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/949314/overview"/></contrib><contrib contrib-type="author"><name><surname>Marik</surname><given-names>Paul E.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/52605/overview"/></contrib><contrib contrib-type="author"><name><surname>Dominguez-Rodriguez</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/938872/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Cell Systems and Anatomy, UT Health San Antonio</institution>, <addr-line>San Antonio, TX</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Physiology, Faculty of Medicine, University of La Laguna</institution>, <addr-line>San Crist&#x000f3;bal de La Laguna</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School</institution>, <addr-line>Norfolk</addr-line>, <addr-line>VA</addr-line>, <country>United States</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Cardiology, Hospital Universitario de Canarias</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country></aff><aff id="aff5"><sup>5</sup><institution>Facultad de Ciencias de la Salud, Universidad Europea de Canarias</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country></aff><aff id="aff6"><sup>6</sup><institution>CIBER de enfermedades CardioVasculares (CIBERCV)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Irene Crespo, University of Le&#x000f3;n, Spain; Abdul Alim Al-Bari, University of Rajshahi, Bangladesh; Javier Gonz&#x000e1;lez-Gallego, University of Le&#x000f3;n, Spain</p></fn><corresp id="c001">*Correspondence: Russel J. Reiter <email>reiter@uthscsa.edu</email></corresp><corresp id="c002">Alberto Dominguez-Rodriguez <email>adrvdg@hotmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases &#x02013; Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>7</volume><elocation-id>226</elocation-id><history><date date-type="received"><day>06</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>04</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Reiter, Abreu-Gonzalez, Marik and Dominguez-Rodriguez.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Reiter, Abreu-Gonzalez, Marik and Dominguez-Rodriguez</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The coronavirus, COVID-19, has infected hundreds of thousands and killed tens of thousands of individuals worldwide. This highly infectious condition continues to ravage the world population and has yet to reach it peak infective rate in some countries. Many conventional drugs including hydroxychloroquine/chloroquine, lopinavir, remdesivir, etc., have been repurposed as treatments for this often deadly disease, but there is no specifically-designed effective drug available; also, the drugs mentioned have significant side effects and their efficacy is unknown. New drugs and vaccines are being designed as COVID-19 treatment, but their development and testing will require months to years. Time is not a luxury that this crisis has. Thus, there is a serious unmet need for the identification of currently-available and safe molecules which can be used to slow or treat COVID-19 disease. Here, we suggest melatonin be given consideration for prophylactic use or treatment alone or in combination with other drugs. Melatonin's multiple actions as an anti-inflammatory, anti-oxidant, and anti-viral (against other viruses) make it a reasonable choice for use. Melatonin is readily available, can be easily synthesized in large quantities, is inexpensive, has a very high safety profile and can be easily self-administered. Melatonin is endogenously-produced molecule in small amounts with its production diminishing with increased age. Under the current critical conditions, large doses of melatonin alone or in combination with currently-recommended drugs, e.g., hydroxychloroquine/chloroquine, to resist COVID-19 infection would seem judicious.</p></abstract><kwd-group><kwd>melatonin</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>treatment-drug</kwd><kwd>prevention &#x00026; control</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fundaci&#x000c3;&#x000b3;n Canaria de Investigaci&#x000c3;&#x000b3;n y Salud<named-content content-type="fundref-id">10.13039/100007650</named-content></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="51"/><page-count count="7"/><word-count count="4602"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>In the past 20 years, two coronavirus epidemics that originated in China caused large-scale pandemics that involved over 20 countries leading to ~8,000 cases and 800 deaths. In 2002 the Middle East respiratory syndrome coronavirus produced 2,500 cases with infection and caused 800 deaths. The coronavirus disease 2019 (COVID-19) is highly contagious and has quickly spread globally (<xref rid="B1" ref-type="bibr">1</xref>). Using mathematical models, the attack rate of COVID-19 suggests an estimate of reproduction (R0) to be 2&#x02013;3 indicating that 60% of the population will likely become infected (<xref rid="B2" ref-type="bibr">2</xref>). As of March 31, 2020 there have been 777,798 cases of COVID-19 reported worldwide, with 37,272 fatalities (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>The cardinal symptoms of COVID-19 are cough, fever, and shortness of breath. These symptoms appear 2&#x02013;14 days after infection (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). The clinical picture varies from pausymptomatic to more serious clinical situations such as severe respiratory failure, sepsis, shock, and multiple organ dysfunction syndrome (<xref rid="B6" ref-type="bibr">6</xref>). Currently, there is no specific treatment for COVID-19, so drugs need to be developed or reused to end the pandemic. The World Health Organization has launched a clinical trial called SOLIDARITY to investigate 4 potential treatments: lopinavir and ritonavir plus interferon-beta, lopinavir and ritonavir, chloroquine/hydroxychloroquine, and remdesivir (<xref rid="B7" ref-type="bibr">7</xref>). The medical profession has quickly realized that there is no cure for this disease and vaccines will not be available for several months. This leaves a large unmet need for safe and effective treatments for COVID-19-infected patients. Obviously, there is a very urgent need for a cheap, viable, and readily available treatment such as melatonin (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Melatonin is synthesized from tryptophan in the pineal gland and by almost all the organs of the body, since its production is associated with mitochondria. It is noteworthy that high levels of melatonin play positive roles in health and aging. Melatonin, a well-known chronobiotic, is also a promising adjunctive drug for viral infections due to its anti-inflammatory, antiapoptotic, immunomodulatory, and powerful antioxidant properties (<xref rid="B8" ref-type="bibr">8</xref>). Herein, we review the current evidence for a role of melatonin as a COVID-19 treatment. Since the clinical data is very limited, we propose the use of melatonin in patients with COVID-19 to reduce morbidity and mortality.</p></sec><sec id="s2"><title>Rationale for Melatonin Use in Patients With COVID-19</title><p>Little is known about the crucial factors of disease severity and immune alteration produced by COVID-19 infection in humans (<xref rid="B9" ref-type="bibr">9</xref>). Cytokines and chemokines play important roles in immunity, demonstrating that an exaggerated immune response causes lung damage and a greater probability of death. In individuals infected with COVID-19, interleukin (IL)&#x02212;10, 6 and tumour necrosis factor (TNF) -&#x003b1; are increased during the disease. The more severe patients have very high levels of IL-10, IL-6, and TNF&#x003b1;; and fewer CD8+ and CD4+ T cells (<xref rid="B9" ref-type="bibr">9</xref>). Previous animal studies have shown that the cytokine storm dampens adaptive immunity against COVID-19 infection (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Chen et al. (<xref rid="B11" ref-type="bibr">11</xref>) have recently demonstrated immunological differences between moderate vs. severe COVID-19 patients. They demonstrate that CD8+ and CD4+ T cell numbers decrease significantly in patients with severe COVID-19. In patients with moderate COVID-19 the concentrations of IL-10, IL-6, and TNF&#x003b1; are within normal limits, and in the most severe patients they are very high. These cytokines are produced by macrophages and are involved in the cytokine storm (<xref rid="B12" ref-type="bibr">12</xref>). The cytokine storm magnifies the danger signal of the virus invasion, but also leads to destructive inflammation and host cell damage (<xref rid="B13" ref-type="bibr">13</xref>). In turn, the components released from damaged cells, particularly from stressed mitochondria, including mitochondrial DNA, cardiolipin, cytochrome C and also segments of nuclear DNA are recognized as damage associated molecular patterns by intra and intercellular immune molecules including toll-like receptors 4,7, and 9. Cyclic GMP-AMP synthase triggers a further large-scale proinflammatory cytokine release known as the &#x0201c;secondary cytokine storm&#x0201d;. If this vicious cycle is not interrupted, it results in widespread apoptosis, pyroptosis, and necrosis even of non-infected cells (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>COVID-19 infection may attack the melatonin synthetic pathway resulting in reduced melatonin levels at a time when melatonin is most needed (<xref rid="B14" ref-type="bibr">14</xref>). The uncontrolled innate immune response promotes a massive inflammatory reaction and causes irreversible tissue damage and mortality. Melatonin is a potent antioxidant and immune regulator that not only suppresses oxidative stress but also controls the innate immune response and promotes the adaptive immune response (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). The pineal gland produces and maintains the concentration of melatonin in the blood. The melatonin synthesized in the pineal gland is &#x0003c;5% of the total melatonin produced. The melatonin produced in the mitochondria is not discharged into the circulation, but is used by the cells that produce it (<xref rid="B15" ref-type="bibr">15</xref>). If patients do not generate sufficient amounts of melatonin their health status is likely compromised (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Autophagy plays an important role both in the antiviral defense responses and in the promotion of the different stages of the viral life cycle. The fact that melatonin is a regulator of autophagy due to its properties as a potent antioxidant and suppressor of endoplasmic reticulum stress suggests a potential beneficial role for this molecule in the management of some viral infections (<xref rid="B17" ref-type="bibr">17</xref>). Viruses, including Ebola, dengue, encephalomyocarditis, Venezuelan equine encephalitis, rabbit hemorrhagic disease, human papilloma, and inter alia, have demonstrated the success of melatonin in protecting against viral infections. There is no evidence that melatonin is viricidal but rather it reduces the severity of these infections (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). Melatonin's beneficial effects derive from its anti-inflammatory properties, free radical scavenging activity, and immunomodulatory functions.</p></sec><sec id="s3"><title>Use of Melatonin for Treatment of COVID-19 in the Population</title><p>Pharmaceutical laboratories are competing to identify vaccines for COVID-19. According to Benjami Neuman, a virologist, &#x0201c;it is difficult to immunize against the coronavirus, since there has never been a successful human vaccine against any member of the coronavirus family&#x0201d; (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>The cytokine storm leads to acute cardiac injury, acute respiratory distress syndrome, and infection, leading to generalized sepsis and multisystem failure, which may lead to death (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Thus, preventing the cytokine storm may be key for the treatment of COVID-19 infected patients. Since there is a lack of effective therapies and immunological treatments may be insufficient, melatonin, owing to its multiple actions as summarized by Zhang et al. (<xref rid="B8" ref-type="bibr">8</xref>), may have beneficial effects in preventing or attenuating the cytokine storm and reducing morbidity and mortality from this disease.</p><sec><title>Melatonin, the Elderly &#x00026; COVID-19</title><p>A relationship between melatonin and aging has been suggested, due to a decrease in the concentration of nocturnal melatonin levels in the elderly (<xref rid="B23" ref-type="bibr">23</xref>). It has been hypothesized that melatonin can prolong life (<xref rid="B24" ref-type="bibr">24</xref>). The relationship of melatonin with aging involves three potential mechanisms: first, melatonin is a key molecule in regular circadian rhythms (<xref rid="B25" ref-type="bibr">25</xref>); second, melatonin prevents cardiolipin peroxidation and regulates the synthesis of mitochondrial proteins (<xref rid="B26" ref-type="bibr">26</xref>); finally, melatonin secreted by leukocytes exerts a powerful immunomodulatory function (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>Wu and colleagues have recently shown that advanced age is a poor prognostic factor in patients with COVID-19. This is due to the fact that in the elderly their immune response and physiological functions are decreased as a result of age; therefore, they are more likely to develop severe pneumonia due to COVID-19 (<xref rid="B25" ref-type="bibr">25</xref>). Recent studies have shown that high levels of melatonin in the blood play a positive role in health and aging (<xref rid="B27" ref-type="bibr">27</xref>). These findings support a rationale for melatonin use in elderly suffering with COVID-19.</p></sec><sec><title>Melatonin, Medical Comorbidities &#x00026; COVID-19</title><p>Aging is a biological process that contributes to an increase in cardiovascular morbidity and mortality. In the HEIJO-KYO cohort (cohort of elderly Japanese patients), urinary excretion of melatonin was associated with reduced nocturnal systolic blood pressure, independent of other cardiovascular risk factors. More precisely, an increase in urinary melatonin excretion from 4.2 to 10.5 &#x003bc;g caused a 2 mmHg decrease in nocturnal systolic blood pressure. Patients who took melatonin at a dose of 2&#x02013;5 mg/day for 7&#x02013;90 days uniformly showed a reduction in night-time blood pressure (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>).</p><p>Obesity is a risk factor for cardiovascular disease. In different studies, melatonin has been shown to have anti-obesity effects (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Taking melatonin reduces intra-abdominal visceral fat deposition and body weight. Its antiobesogenic effects are believed to be due to two processes: regulation of energy reserves and a relationship with the physiological processes of wakefulness/sleep rhythm (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>Diabetes is a risk factor for the development of cardiovascular diseases. Several studies have shown a functional interaction between insulin and melatonin, showing that diabetic subjects have a lower concentration of melatonin (<xref rid="B33" ref-type="bibr">33</xref>). Furthermore, decreased blood melatonin levels have been documented in patients with insulin resistance or glucose intolerance (<xref rid="B34" ref-type="bibr">34</xref>). The results of several studies suggest that low melatonin production is associated with an increased risk of cardiovascular disease (<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B37" ref-type="bibr">37</xref>).</p><p>Several studies have shown that 75% of COVID-19 patients have 1 or 2 medical comorbidities (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Other authors have reported that patients with hypertension, obesity, and diabetes are more likely to develop more severe COVID-19 infection, including death (<xref rid="B40" ref-type="bibr">40</xref>). The occurrence of heart failure and myocardial infarction is plausible in these patients. The immune system of these patients is altered, with a reduced immune response (<xref rid="B40" ref-type="bibr">40</xref>). Furthermore, obesity contributes to various chronic diseases; decreased immunity and subsequently an increased risk of infection (<xref rid="B41" ref-type="bibr">41</xref>). Therefore, medical comorbidities are a risk factor for a poor prognosis for patients with COVID-19. Published reports routinely show that melatonin reduces the consequences of the comorbidities in patients with COVID-19.</p></sec><sec><title>Melatonin in COVID-19 Outbreak: Prevention in the Population (Elderly &#x00026; Medical Comorbidities)</title><p>While physiological melatonin concentrations in biological fluids oscillate between 10<sup>&#x02212;10</sup> and 10<sup>&#x02212;11</sup> M range, a concentration of 10<sup>&#x02212;5</sup> M is required to elicit significant pharmacological effects (<xref rid="B42" ref-type="bibr">42</xref>). Melatonin protects against cellular damage induced by reactive oxidative species, thus justifying the need of a more generous supplementation of exogenous melatonin in life-threatening pathologies. Oral melatonin use by humans is generally considered safe, with minor side effects including headache, drowsiness, etc. (<xref rid="B43" ref-type="bibr">43</xref>). To date, the best dose of melatonin in older adults has not been determined, as its endogenous levels are subject to altered pharmacokinetics. This causes intra-individual variability (<xref rid="B44" ref-type="bibr">44</xref>). In a meta-analysis of 50 studies, some of which were not blinded, the efficacy of oral melatonin administration (1&#x02013;20 mg) was evaluated caused only a few minor adverse side effects, commonly fatigue, and drowsiness (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>In elderly patients with medical comorbidities, treatment with melatonin is beneficial, as it strengthens the immune response. We suggest a daily dose of ~3 mg to a maximum of 10 mg, 30&#x02013;60 min before bedtime to better simulate the normal physiological circadian rhythm of melatonin (<xref ref-type="fig" rid="F1">Figure 1</xref>). Furthermore, it may be beneficial in people who are at high risk of contracting COVID-19 infection, local health workers, where preventive treatment with melatonin would favor maximizing the immune response, along with anti-inflammatory and antioxidant effects. A daily dose of roughly 40 mg or higher would not seem an inappropriate amount (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Prevention of COVID-19 infections in the elderly, in individuals with comorbidities and in health care workers.</p></caption><graphic xlink:href="fmed-07-00226-g0001"/></fig></sec><sec><title>Melatonin in COVID-19 Outbreak: Treatment in the Hospital</title><p>The world is now facing a pandemic of COVID-19, for which no proven specific therapies are available, other than supportive care. In China, France, Spain, and Italy, a large number of patients have received compassionate use therapies. These therapies have been mostly given without controls, except for a few randomized trials initiated in China, and more recently in the US (<xref rid="B46" ref-type="bibr">46</xref>). In the 2014 Ebola outbreak, a randomized clinical trial was implemented and successfully launched during the outbreak; however, it was too late for the trials to be completed in time to be helpful to the currently or soon-to-be infective population (<xref rid="B47" ref-type="bibr">47</xref>). In our view, this tragedy cannot be repeated. The COVID-19 pandemic is catastrophic, even though different countries have implemented strict control measures.</p><p>Good medical practice requires the physician to use legally available medications according to knowledge-based evidence. If physicians use a product for an indication that is not currently approved, they must base its use on sound scientific reasons and sound medical evidence. Melatonin should be considered a treatment option for this deadly disease.</p><p>Melatonin has been shown to be clinically useful in sepsis (<xref rid="B43" ref-type="bibr">43</xref>), where the clinical features parallel those of COVID-19 viral infection; moreover, melatonin has been demonstrated to relieve many of the symptoms of other viral infections (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Given the current worldwide situation and in consideration of evidence-based medicine, the efficacy of melatonin and its high pharmacological safety profile supports its use in the treatment of infectious diseases, such as COVID-19. Melatonin can also be useful as a supplement with other treatment (hydroxychloroquine/chloroquine, lopinavir, remidisvir, etc).</p><p>Our research group has extensive experience in the use of melatonin in the context of cardiovascular physiology. Melatonin can be administered at a total dose of at least 120 to 1,000 &#x003bc;g/kg/subject weight and intravenously with a high safety profile (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). An aggressive approach is required to prevent coronavirus disease progression and mechanical ventilation. Nordlund and Lerner (<xref rid="B49" ref-type="bibr">49</xref>) published a report years ago in which he gave humans one gram of melatonin daily for a month with no untoward effect. Melatonin has a large safety margin without serious adverse effects.</p><p>Our doses are based in an article recently published by Ramos et al. (<xref rid="B50" ref-type="bibr">50</xref>). The authors demonstrated that when we extrapolated effective animal doses to human for a 70 kg adult, the results ranged from 19 to 1,527 mg per day. As there is no time or clinical trials to test the efficacy of melatonin at different concentrations, we suggest the use of melatonin (100 or 400 mg per day) as an adjunct, especially if no efficient direct anti-viral treatment is available (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Therapeutic algorithm for use of melatonin in patients with COVID-19. Melatonin will likely reduce the toxicity of chloroquine and increase its efficacy. BID, twice daily; PO, per oral.</p></caption><graphic xlink:href="fmed-07-00226-g0002"/></fig></sec></sec><sec sec-type="conclusions" id="s4"><title>Conclusion</title><p>The COVID-19 pandemic has infected hundreds of thousands and killed tens of thousands of individuals worldwide. Time is not a luxury that this crisis has. The high mortality is caused by the uncontrolled innate immune response and destructive inflammation. Melatonin is a molecule that negatively regulates the overreaction of the innate immune response and excess inflammation, promoting adaptive immune activity. Moreover, the indole is an endogenous molecule, produced in small amounts, whose synthesis diminishes with increased age. These finding, together with those recently summarized by Anderson and Reiter (<xref rid="B51" ref-type="bibr">51</xref>) and Zhang et al. (<xref rid="B8" ref-type="bibr">8</xref>), support the use of melatonin in patients with COVID-19. We agree with the suggestion by those authors that melatonin should be given consideration for prophylactic use or treatment alone or in combination with other drugs, and propose a therapeutic algorithm for use in patients. Melatonin is readily available, can be easily synthesized in large quantities, is inexpensive, has a very high safety profile and can be easily self-administered.</p></sec><sec id="s5"><title>Author Contributions</title><p>RR: conceptualization, writing-review, and editing. PA-G and PM: writing-review and editing. AD-R: resources, writing original draft, review, and editing. All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p><sec id="s6"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This research was funded by Fundaci&#x000f3;n Canaria Instituto de Investigaci&#x000f3;n Sanitaria de Canarias (FIISC) (PIFUN11/18).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chafekar</surname><given-names>A</given-names></name><name><surname>Fielding</surname><given-names>BC</given-names></name></person-group>. <article-title>MERS-CoV: understanding the latest human coronavirus threat</article-title>. <source>Viruses</source>. (<year>2018</year>) <volume>10</volume>:<fpage>E93</fpage>. <pub-id pub-id-type="doi">10.3390/v10020093</pub-id><?supplied-pmid 29495250?><pub-id pub-id-type="pmid">29495250</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flahault</surname><given-names>A</given-names></name></person-group>. <article-title>Has China faced only a herald wave of SARS-CoV-2?</article-title>
<source>Lancet</source>. (<year>2020</year>) <volume>395</volume>:<fpage>947</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30521-3</pub-id><?supplied-pmid 32145187?><pub-id pub-id-type="pmid">32145187</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Centre for Disease Prevention Control,</collab></person-group> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/novel-coronavirus-china">https://www.ecdc.europa.eu/en/novel-coronavirus-china</ext-link> (accessed March 31, 2020).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group>. <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>1708</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><?supplied-pmid 32109013?><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>1177</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2001737</pub-id><?supplied-pmid 32074444?><pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>MH</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Loeb</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)</article-title>. <source>Intensive Care Med</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1007/s00134-020-06022-5.</pub-id> [Epub ahead of print].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahase</surname><given-names>E</given-names></name></person-group>. <article-title>Covid-19: what treatments are being investigated?</article-title>
<source>BMJ.</source> (<year>2020</year>) <volume>368</volume>:<fpage>m1252</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1252</pub-id><?supplied-pmid 32217607?><pub-id pub-id-type="pmid">32217607</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Di</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>COVID-19: Melatonin as a potential adjuvant treatment</article-title>. <source>Life Sci.</source> (<year>2020</year>) <volume>250</volume>:<fpage>11758</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117583</pub-id><?supplied-pmid 32217117?><pub-id pub-id-type="pmid">32217117</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title>. <source>Front. Immunol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>827</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmid">32425950</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group>. <article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title>. <source>Cell Host Microbe</source>. (<year>2016</year>) <volume>19</volume>:<fpage>181</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Clinical and immunologic features in severe and moderate coronavirus disease 2019</article-title>. <source>J Clin Invest</source>. (<year>2020</year>) <volume>130</volume>:<fpage>2620</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><pub-id pub-id-type="pmid">32217835</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing</article-title>. <source>medRxiv</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1101/2020.02.23.20026690.</pub-id> [Epub ahead of print].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>P</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Lethal influenza A virus preferentially activates TLR3 and triggers a severe inflammatory response</article-title>. <source>Virus Res</source>. (<year>2018</year>) <volume>257</volume>:<fpage>102</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2018.09.012</pub-id><?supplied-pmid 30248373?><pub-id pub-id-type="pmid">30248373</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>ME</given-names></name><name><surname>Shaban</surname><given-names>MG</given-names></name><name><surname>Mackin</surname><given-names>SR</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Murine coronavirus infection activates the aryl hydrocarbon receptor in an indoleamine 2,3-dioxygenase-independent manner, contributing to cytokine modulation and proviral TCDD-inducible-PARP expression</article-title>. <source>J Virol</source>. (<year>2020</year>) <volume>94</volume>:<fpage>e01743</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01743-19</pub-id><?supplied-pmid 31694960?><pub-id pub-id-type="pmid">31694960</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-&#x003b1;</article-title>. <source>Int Immunopharmacol.</source> (<year>2020</year>) <volume>83</volume>:<fpage>106365</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106365</pub-id><?supplied-pmid 32172204?><pub-id pub-id-type="pmid">32172204</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedova</surname><given-names>KA</given-names></name><name><surname>Bernikova</surname><given-names>OG</given-names></name><name><surname>Cuprova</surname><given-names>JI</given-names></name><name><surname>Ivanova</surname><given-names>AD</given-names></name><name><surname>Kutaeva</surname><given-names>GA</given-names></name><name><surname>Pliss</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Association between antiarrhythmic, electrophysiological, and antioxidative effects of melatonin in ischemia/reperfusion</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>:<fpage>E6331</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20246331</pub-id><?supplied-pmid 31847485?><pub-id pub-id-type="pmid">31847485</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boga</surname><given-names>JA</given-names></name><name><surname>Caballero</surname><given-names>B</given-names></name><name><surname>Potes</surname><given-names>Y</given-names></name><name><surname>Perez-Martinez</surname><given-names>Z</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Vega-Naredo</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Therapeutic potential of melatonin related to its role as an autophagy regulator: a review</article-title>. <source>J Pineal Res</source>. (<year>2019</year>) <volume>66</volume>:<fpage>e12534</fpage>. <pub-id pub-id-type="doi">10.1111/jpi.12534</pub-id><?supplied-pmid 30329173?><pub-id pub-id-type="pmid">30329173</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Markus</surname><given-names>RP</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name></person-group>. <article-title>Ebola virus: melatonin as a readily available treatment option</article-title>. <source>J Med Virol</source>. (<year>2015</year>) <volume>87</volume>:<fpage>537</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24130</pub-id><?supplied-pmid 25611054?><pub-id pub-id-type="pmid">25611054</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paemanee</surname><given-names>A</given-names></name><name><surname>Hitakarun</surname><given-names>A</given-names></name><name><surname>Roytrakul</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name></person-group>. <article-title>Screening of melatonin, &#x003b1;-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity</article-title>. <source>BMC Res Notes</source>. (<year>2018</year>) <volume>11</volume>:<fpage>307</fpage>. <pub-id pub-id-type="doi">10.1186/s13104-018-3417-3</pub-id><?supplied-pmid 29769094?><pub-id pub-id-type="pmid">29769094</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crespo</surname><given-names>I</given-names></name><name><surname>Miguel</surname><given-names>BS</given-names></name><name><surname>Laliena</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>M</given-names></name><name><surname>Culebras</surname><given-names>JM</given-names></name><name><surname>Gonz&#x000e1;lez-Gallego</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin</article-title>. <source>J Pineal Res</source>. (<year>2010</year>) <volume>49</volume>:<fpage>193</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-079X.2010.00787.x</pub-id><?supplied-pmid 20609075?><pub-id pub-id-type="pmid">20609075</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valero</surname><given-names>N</given-names></name><name><surname>Mosquera</surname><given-names>J</given-names></name><name><surname>Alcocer</surname><given-names>S</given-names></name><name><surname>Bonilla</surname><given-names>E</given-names></name><name><surname>Salazar</surname><given-names>J</given-names></name><name><surname>&#x000c1;lvarez-Mon</surname><given-names>M</given-names></name></person-group>. <article-title>Melatonin, minocycline and ascorbic acid reduce oxidative stress and viral titers and increase survival rate in experimental <italic>Venezuelan equine encephalitis</italic></article-title>. <source>Brain Res</source>. (<year>2015</year>) <volume>1622</volume>:<fpage>368</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2015.06.034</pub-id><?supplied-pmid 26168898?><pub-id pub-id-type="pmid">26168898</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>MedicalXpress Breaking News and Events</collab></person-group>
<source>Coronavirus Drugs: Who's</source>. (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.mdlinx.com/painmanagement/top-medical-news/article/index.cfm/?publish_dt=03-17-2020&#x00026;rowNum=7621393&#x00026;_rw=true&#x00026;utm_source=alert&#x00026;utm_medium=email&#x00026;utm_~campaign=ajm_49664&#x00026;">www.mdlinx.com/painmanagement/top-medical-news/article/index.cfm/?publish_dt=03-17-2020&#x00026;rowNum=7621393&#x00026;_rw=true&#x00026;utm_source=alert&#x00026;utm_medium=email&#x00026;utm_~campaign=ajm_49664&#x00026;</ext-link> (accessed March 16, 2020).</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>JF</given-names></name><name><surname>Zitting</surname><given-names>KM</given-names></name><name><surname>Chinoy</surname><given-names>ED</given-names></name></person-group>. <article-title>Aging and circadian rhythms</article-title>. <source>Sleep Med Clin</source>. (<year>2015</year>) <volume>10</volume>:<fpage>423</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsmc.2015.08.002</pub-id><?supplied-pmid 26568120?><pub-id pub-id-type="pmid">26568120</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandi-Perumal</surname><given-names>SR</given-names></name><name><surname>BaHammam</surname><given-names>AS</given-names></name><name><surname>Brown</surname><given-names>GM</given-names></name><name><surname>Spence</surname><given-names>DW</given-names></name><name><surname>Bharti</surname><given-names>VK</given-names></name><name><surname>Kaur</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes</article-title>. <source>Neurotox Res</source>. (<year>2013</year>) <volume>23</volume>:<fpage>267</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-012-9337-4</pub-id><?supplied-pmid 22739839?><pub-id pub-id-type="pmid">22739839</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)</article-title>. <source>J Intern Med.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1111/joim.13063.</pub-id> [Epub ahead of print]. <?supplied-pmid 32220033?><pub-id pub-id-type="pmid">32220033</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majidinia</surname><given-names>M</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Shakouri</surname><given-names>SK</given-names></name><name><surname>Mohebbi</surname><given-names>I</given-names></name><name><surname>Rastegar</surname><given-names>M</given-names></name><name><surname>Kaviani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The multiple functions of melatonin in regenerative medicine</article-title>. <source>Ageing Res Rev.</source> (<year>2018</year>) <volume>45</volume>:<fpage>33</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2018.04.003</pub-id><?supplied-pmid 29630951?><pub-id pub-id-type="pmid">29630951</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardeland</surname><given-names>R</given-names></name></person-group>. <article-title>Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms</article-title>. <source>J Pineal Res</source>. (<year>2013</year>) <volume>55</volume>:<fpage>325</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1111/jpi.12090</pub-id><?supplied-pmid 24112071?><pub-id pub-id-type="pmid">24112071</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obayashi</surname><given-names>K</given-names></name><name><surname>Saeki</surname><given-names>K</given-names></name><name><surname>Tone</surname><given-names>N</given-names></name><name><surname>Kurumatani</surname><given-names>N</given-names></name></person-group>. <article-title>Relationship between melatonin secretion and nighttime blood pressure in elderly individuals with and without antihypertensive treatment: a cross-sectional study of the HEIJO-KYO cohort</article-title>. <source>Hypertens Res</source>. (<year>2014</year>) <volume>37</volume>:<fpage>908</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/hr.2014.99</pub-id><?supplied-pmid 24849270?><pub-id pub-id-type="pmid">24849270</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borghi</surname><given-names>C</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name></person-group>. <article-title>Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses</article-title>. <source>Br J Clin Pharmacol.</source> (<year>2017</year>) <volume>83</volume>:<fpage>163</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.12902</pub-id><?supplied-pmid 26852373?><pub-id pub-id-type="pmid">26852373</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubin</surname><given-names>DG</given-names></name><name><surname>Gubin</surname><given-names>GD</given-names></name><name><surname>Gapon</surname><given-names>LI</given-names></name><name><surname>Weinert</surname><given-names>D</given-names></name></person-group>. <article-title>Daily melatonin administration attenuates age-dependent disturbances of cardiovascular rhythms</article-title>. <source>Curr Aging Sci</source>. (<year>2016</year>) <volume>9</volume>:<fpage>5</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.2174/1874609809666151130220011</pub-id><?supplied-pmid 26632428?><pub-id pub-id-type="pmid">26632428</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imenshahidi</surname><given-names>M</given-names></name><name><surname>Karimi</surname><given-names>G</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group>
<article-title>Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review. Naunyn Schmiedebergs</article-title>
<source>Arch Pharmacol.</source> (<year>2020</year>) <volume>393</volume>:<fpage>521</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1007/s00210-020-01822-4</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prado</surname><given-names>NJ</given-names></name><name><surname>Ferder</surname><given-names>L</given-names></name><name><surname>Manucha</surname><given-names>W</given-names></name><name><surname>Diez</surname><given-names>ER</given-names></name></person-group>. <article-title>Anti-inflammatory effects of melatonin in obesity and hypertension</article-title>. <source>Curr Hypertens Rep</source>. (<year>2018</year>) <volume>20</volume>:<fpage>45</fpage>. <pub-id pub-id-type="doi">10.1007/s11906-018-0842-6</pub-id><?supplied-pmid 29744660?><pub-id pub-id-type="pmid">29744660</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipolla-Neto</surname><given-names>J</given-names></name><name><surname>Amaral</surname><given-names>FG</given-names></name><name><surname>Afeche</surname><given-names>SC</given-names></name><name><surname>Tan</surname><given-names>DX</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name></person-group>. <article-title>Melatonin, energy metabolism, and obesity: a review</article-title>. <source>J Pineal Res.</source> (<year>2014</year>) <volume>56</volume>:<fpage>371</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/jpi.12137</pub-id><?supplied-pmid 24654916?><pub-id pub-id-type="pmid">24654916</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reutrakul</surname><given-names>S</given-names></name><name><surname>Sumritsopak</surname><given-names>R</given-names></name><name><surname>Saetung</surname><given-names>S</given-names></name><name><surname>Chanprasertyothin</surname><given-names>S</given-names></name><name><surname>Chailurkit</surname><given-names>LO</given-names></name><name><surname>Anothaisintawee</surname><given-names>T</given-names></name></person-group>. <article-title>Lower nocturnal urinary 6-sulfatoxymelatonin is associated with more severe insulin resistance in patients with prediabetes</article-title>. <source>Neurobiol Sleep Circadian Rhythms</source>. (<year>2017</year>) <volume>4</volume>:<fpage>10</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbscr.2017.06.001</pub-id><?supplied-pmid 31236502?><pub-id pub-id-type="pmid">31236502</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Abreu-Gonzalez</surname><given-names>P</given-names></name><name><surname>Piccolo</surname><given-names>R</given-names></name><name><surname>Galasso</surname><given-names>G</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name></person-group>. <article-title>Melatonin is associated with reverse remodeling after cardiac resynchronization therapy in patients with heart failure and ventricular dyssynchrony</article-title>. <source>Int J Cardiol.</source> (<year>2016</year>) <volume>221</volume>:<fpage>359</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.07.056</pub-id><?supplied-pmid 27404706?><pub-id pub-id-type="pmid">27404706</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Abreu-Gonzalez</surname><given-names>P</given-names></name><name><surname>de la Torre-Hernandez</surname><given-names>JM</given-names></name><name><surname>Consuegra-Sanchez</surname><given-names>L</given-names></name><name><surname>Piccolo</surname><given-names>R</given-names></name><name><surname>Gonzalez-Gonzalez</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial)</article-title>. <source>Am J Cardiol</source>. (<year>2017</year>) <volume>120</volume>:<fpage>522</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0735-1097(17)34668-5</pub-id><?supplied-pmid 28645475?><pub-id pub-id-type="pmid">28645475</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Abreu-Gonzalez</surname><given-names>P</given-names></name><name><surname>de la Torre-Hernandez</surname><given-names>JM</given-names></name><name><surname>Gonzalez-Gonzalez</surname><given-names>J</given-names></name><name><surname>Garcia-Camarero</surname><given-names>T</given-names></name><name><surname>Consuegra-Sanchez</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial</article-title>. <source>J Pineal Res</source>. (<year>2017</year>) <volume>62</volume>. <pub-id pub-id-type="doi">10.1111/jpi.12374</pub-id><?supplied-pmid 27736028?><pub-id pub-id-type="pmid">27736028</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLaren</surname><given-names>G</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name></person-group>. <article-title>Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation</article-title>. <source>JAMA.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1001/jama.2020.2342.</pub-id> [Epub ahead of print]. <?supplied-pmid 32074258?><pub-id pub-id-type="pmid">32074258</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>ZD</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>KF</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Yi</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020</article-title>. <source>Emerg Infect Dis.</source> (<year>2020</year>) <volume>26</volume>:<fpage>1052</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3201/eid2605.200198</pub-id><?supplied-pmid 32091386?><pub-id pub-id-type="pmid">32091386</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Safavi-Naeini</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Vardeny</surname><given-names>O</given-names></name></person-group>. <article-title>Potential effects of coronaviruses on the cardiovascular system: a review</article-title>. <source>JAMA Cardiol</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1286.</pub-id> [Epub ahead of print]. <?supplied-pmid 32219363?><pub-id pub-id-type="pmid">32219363</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttunen</surname><given-names>R</given-names></name><name><surname>Syrj&#x000e4;nen</surname><given-names>J</given-names></name></person-group>. <article-title>Obesity and the risk and outcome of infection</article-title>. <source>Int J Obes.</source> (<year>2013</year>) <volume>37</volume>:<fpage>333</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/ijo.2012.62.</pub-id> [Epub ahead of print]. <?supplied-pmid 22546772?><pub-id pub-id-type="pmid">22546772</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>LM</given-names></name><name><surname>Sampson</surname><given-names>JN</given-names></name><name><surname>Chu</surname><given-names>LW</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Andriole</surname><given-names>G</given-names></name><name><surname>Church</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Individual variations in serum melatonin levels through time: implications for epidemiologic studies</article-title>. <source>PLoS ONE.</source> (<year>2013</year>) <volume>8</volume>:<fpage>e83208</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0083208</pub-id><?supplied-pmid 24376664?><pub-id pub-id-type="pmid">24376664</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colunga Biancatelli</surname><given-names>RML</given-names></name><name><surname>Berrill</surname><given-names>M</given-names></name><name><surname>Mohammed</surname><given-names>YH</given-names></name><name><surname>Marik</surname><given-names>PE</given-names></name></person-group>. <article-title>Melatonin for the treatment of sepsis: the scientific rationale</article-title>. <source>J Thorac Dis.</source> (<year>2020</year>) <volume>12</volume> (<issue>Suppl 1</issue>):<fpage>S54</fpage>&#x02013;<lpage>S65</lpage>. <pub-id pub-id-type="doi">10.21037/jtd.2019.12.85</pub-id><?supplied-pmid 32148926?><pub-id pub-id-type="pmid">32148926</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vural</surname><given-names>EM</given-names></name><name><surname>van Munster</surname><given-names>BC</given-names></name><name><surname>de Rooij</surname><given-names>SE</given-names></name></person-group>. <article-title>Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature</article-title>. <source>Drugs Aging</source>. (<year>2014</year>) <volume>31</volume>:<fpage>441</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s40266-014-0178-0</pub-id><?supplied-pmid 24802882?><pub-id pub-id-type="pmid">24802882</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>HM</given-names></name><name><surname>Steel</surname><given-names>AE</given-names></name></person-group>. <article-title>Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence</article-title>. <source>Complement Ther Med</source>. (<year>2019</year>) <volume>42</volume>:<fpage>65</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctim.2018.11.003</pub-id><?supplied-pmid 30670284?><pub-id pub-id-type="pmid">30670284</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="webpage"><source>Adaptive COVID-19 Treatment Trial,</source>. ClinicalTrials.gov identifier: NCT04280705 (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04280705?term=remdesivir&#x00026;cond=covid-19&#x00026;draw=2&#x00026;rank=5">https://clinicaltrials.gov/ct2/show/NCT04280705?term=remdesivir&#x00026;cond=covid-19&#x00026;draw=2&#x00026;rank=5</ext-link> (accessed April 02, 2020).</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Dodd</surname><given-names>L</given-names></name><name><surname>Proschan</surname><given-names>MA</given-names></name><name><surname>Neaton</surname><given-names>J</given-names></name><name><surname>Neuhaus Nordwall</surname><given-names>J</given-names></name><name><surname>Koopmeiners</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>A randomized, controlled trial of ZMapp for Ebola Virus infection</article-title>. <source>N Engl J Med.</source> (<year>2016</year>) <volume>375</volume>:<fpage>1448</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1604330</pub-id><?supplied-pmid 27732819?><pub-id pub-id-type="pmid">27732819</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name></person-group>. <article-title>Network-based drug repurposing for novel coronavirus 2019-nCov/SARS-CoV-2</article-title>. <source>Cell Discov</source>. (<year>2020</year>) <volume>6</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><?supplied-pmid 32194980?><pub-id pub-id-type="pmid">32194980</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlund</surname><given-names>JJ</given-names></name><name><surname>Lerner</surname><given-names>AB</given-names></name></person-group>. <article-title>The effects of oral melatonin on skin color and on the release of pituitary hormones</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>1977</year>) <volume>45</volume>:<fpage>768</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1210/jcem-45-4-768</pub-id><?supplied-pmid 914981?><pub-id pub-id-type="pmid">914981</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>Farr&#x000e9;-Alins</surname><given-names>V</given-names></name><name><surname>Egea</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez-Mu&#x000f1;oz</surname><given-names>F</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Romero</surname><given-names>A</given-names></name></person-group>. <article-title>Melatonin's efficacy in stroke patients; a matter of dose? A systematic review</article-title>. <source>Toxicol Appl Pharmacol</source>. (<year>2020</year>) <volume>392</volume>:<fpage>114933</fpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2020.114933</pub-id><?supplied-pmid 32112789?><pub-id pub-id-type="pmid">32112789</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name></person-group>. <article-title>Melatonin: roles in influenza, Covid-19, and other viral infections</article-title>. <source>Rev Med Virol</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/rmv.2109.</pub-id> [Epub ahead of print]. <?supplied-pmid 32314850?><pub-id pub-id-type="pmid">32314850</pub-id></mixed-citation></ref></ref-list></back></article>